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ABSTRACT 31 
Staphylococcus aureus can produce small colony variants (SCVs) which express various 32 
phenotypes. Whilst their significance is unclear, SCV propagation may be influenced by 33 
relative fitness, antimicrobial susceptibility and the underlying mechanism. We have 34 
investigated triclosan-induced generation of SCVs in six S. aureus strains, including MRSA. 35 
Parent strains (P0) were repeatedly passaged on concentration gradients of triclosan using a 36 
solid-state exposure system to generate P10. P10 was subsequently passaged without 37 
triclosan to generate X10. Susceptibility to triclosan and 7 antibiotics was assessed at all 38 
stages. For S. aureus ATCC6538, SCVs were further characterised by determining 39 
microbicide susceptibility and competitive fitness. Cellular morphology was examined using 40 
electron microscopy and protein expression evaluated through proteomics. Triclosan 41 
susceptibility in all SCVs (which could be generated from 4/6 strains) was markedly 42 
decreased, whilst antibiotic susceptibility was significantly increased in the majority of cases. 43 
A SCV of S. aureus ATCC6538 exhibited significantly increased susceptibility to all tested 44 
microbicides. Cross-wall formation was impaired in this bacterium, whilst expression of 45 
FabI, a target of triclosan and IsaA, a lytic transglycosylase involved in cell division, was 46 
increased. The P10 SCV was 49% less fit than P0. In summary, triclosan exposure of S. 47 
aureus produced SCVs in 4/6 test bacteria, with decreased triclosan susceptibility but with 48 
generally increased antibiotic susceptibility. A SCV derived from S. aureus ATCC6538 49 
showed reduced competitive fitness, potentially due to impaired cell division. In this SCV, 50 
increased FabI expression could account for reduced triclosan susceptibility, whilst IsaA may 51 
be upregulated in response to cell division defects. 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
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INTRODUCTION 63 
Staphylococcus aureus small colony variants (SCVs) are characterised by low growth rate 64 
and the formation of small non-pigmented colonies (1, 2). They are commonly, but not 65 
exclusively, related to antibiotic exposure (3) and have been shown to display diverse 66 
phenotypic characteristics, including reduced β-haemolysis, coagulase and DNase activity 67 
(4), enhanced intracellular survival (5), impaired biofilm formation (6), reduced virulence (6) 68 
and low intrinsic susceptibility to certain antibiotics, cationic microbicides and antimicrobial 69 
peptides (7, 8). Whilst all SCVs are not physiologically the same, certain SCVs have been  70 
reported to cause persistent skin, bone and device-associated infections and they have been 71 
isolated from patients undergoing prolonged antibiotic therapy (2, 9, 10). Due to their 72 
uncommon morphological features and pin-point colony size, SCVs may be overlooked or 73 
misidentified in clinical microbiology laboratories, potentially confounding their 74 
identification. 75 
The phenotypic variation observed in S. aureus SCVs is often attributed to auxotrophy for 76 
menadione, hemin or thiamine due to mutations in their respective genes. This results in 77 
impaired synthesis of menaquinone and cytochromes causing defects in the electron transport 78 
chain (1, 11, 12). A resulting reduction in transmembrane potential leads to a decrease in 79 
ATP production, which may cause impaired cell wall synthesis as well as a decrease in 80 
growth rate resulting in a smaller bacterial colony size (12, 13). This metabolic change can 81 
also lead to alterations in pigmentation and exotoxin expression (5, 6, 14). 82 
 83 
S. aureus SCVs recovered from clinical specimens taken from the bronchial secretions of 84 
cystic fibrosis (CF) patients have displayed auxotrophy for thymidine due to mutations in 85 
thymidylate synthase (thyA), an enzyme involved in thymidine synthesis through the 86 
production of dTMP (9, 15). Recent studies reveal thyA mutants exhibit resistance to 87 
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trimethoprim–sulfamethoxazole, a common treatment for CF (15). Trimethoprim–88 
sulfamethoxazole inhibits tetrahydrofolic acid production, which is a cofactor for thymidylate 89 
synthase thus involved in thymidine synthesis (16). It is therefore apparent that antibiotic 90 
treatment may provide a selective pressure that favours the selection of SCVs.  91 
 92 
A decrease in transmembrane potential in SCV electron transport-defective mutants may 93 
result in reduced susceptibility to certain antibiotics and cationic microbicides due to a 94 
reduction in cell wall metabolism, lower growth rate and impaired uptake of positively 95 
charged molecules to the bacterial cell (17-19). For example, clinical SCV isolates of S. 96 
aureus have previously shown reduced susceptibility to β-lactams and aminoglycosides (15, 97 
17, 20). Furthermore, it has been suggested that SCVs may potentially gain a survival 98 
advantage within the host by their ability to persist within phagocytes, due in part to a 99 
decrease in α-toxin production, and are therefore shielded from host immune defences as well 100 
as the actions of antibiotics (5, 21, 22). The clinical significance of these purported attributes 101 
however, depends on whether the SCV can revert to full virulence following cessation of 102 
treatment, which in turn depends upon the stability of the responsible mutations and the 103 
relative fitness of the SCV when compared to the parent strain (23, 24). 104 
 105 
Induction of the SCV phenotype in S. aureus after sub-effective exposure to triclosan has 106 
been previously reported (6, 25, 26). Triclosan is a bisphenol microbicide that is often 107 
incorporated into disinfectant washes, toothpastes, cosmetics and household products for the 108 
purpose of antisepsis and disinfection (27-29). Triclosan exerts bacteriostatic activity through 109 
inhibition of FabI, an enoyl-ACP reductase, which participates in fatty acid synthesis (30-32). 110 
At higher concentrations triclosan is bactericidal due to direct effects on the cytoplasmic 111 
membrane (33). Whilst resistance to in-use concentrations of microbicides is rare, certain 112 
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bacteria are reported to have developed a reduced susceptibility to triclosan after sub-113 
inhibitory exposure in vitro (6, 34, 35). This may be due to point mutations in the fabI gene 114 
(36), overexpression of FabI or due to increased efflux pump activity leading to the removal 115 
of the compound from the cell (37, 38). In S. aureus, sub-lethal exposure to triclosan has been 116 
shown to induce the formation of triclosan insusceptible SCVs that display alterations in 117 
metabolism, virulence and reduced susceptibility to gentamicin (6, 35, 39). 118 
 119 
We have previously described the generation of a SCV in S. aureus ATCC 6538 in response 120 
to repeated sub-lethal triclosan exposure (6) which displayed reduced susceptibility to 121 
triclosan, lower growth rate, impaired biofilm formation and reduced pathogenicity when 122 
compared to the parent strain. The current investigation evaluates the effect of triclosan on 123 
the induction of the SCV state in 5 other strains of S. aureus, as well as further characterising 124 
the phenotypic changes in the previously generated SCV with respect to susceptibility to 125 
antibiotics and cationic microbicides, as well as alterations in competitive fitness, cellular 126 
morphology and protein expression. 127 
 128 
MATERIALS AND METHODS 129 
Chemical Reagents and Growth Media. Bacteriological growth media were 130 
purchased from Oxoid (Basingstoke, UK). Chemical reagents were purchased from Sigma-131 
Aldrich (Dorset, UK) unless otherwise stated. Vantocil (a 20% v/v aqueous solution of 132 
PHMB) was obtained from Arch Chemicals Inc. (Manchester, UK).  133 
Bacterial strains and growth media. Staphylococcus aureus strains ATCC 6538 and 134 
ATCC 43300 (MRSA) were supplied by the American Type Culture Collection. Strains 135 
Newman, NCTC 6571, NCTC 13277 (MRSA) and NCTC 13142 (MRSA) were obtained 136 
from Public Health England (Salisbury, UK). Bacteria were grown on Tryptone Soya agar 137 
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(TSA) or Tryptone Soya broth (TSB). Cultures were incubated aerobically at 37˚C for 18-24h 138 
unless otherwise stated. Bacteria were archived at -80˚C prior to triclosan exposure (parent 139 
strain P0), after 10 passages across a triclosan gradient (P10; SCV) and after a further 10 140 
passages in the absence of triclosan (X10). 141 
Selection of isolates with reduced triclosan susceptibility. Reproducible 142 
concentration gradients of triclosan were created on TSA agar by depositing stock solutions 143 
of triclosan (100 μg/ml- 10 mg/ml) with a Wasp II spiral plater (Don Whitley, Shipley, 144 
United Kingdom) (6). Plates were dried for 1 h at room temperature prior to radial deposition 145 
of an overnight suspension of S. aureus and incubated for 4 days aerobically at 37°C. Growth 146 
observed at the highest triclosan concentration was removed and used to inoculate further 147 
gradient plates. This process was repeated for 10 passages. A further 10 passages were 148 
performed on triclosan-free TSA. Isolates (the parent P0 strain), those passaged 10 times on 149 
triclosan (strain P10), and those passaged a further 10 times on triclosan-free TSA (strain 150 
X10) were archived at −80°C for subsequent analyses.  151 
Minimum inhibitory concentrations (MICs) and minimum bactericidal 152 
concentrations (MBCs). MIC values were determined using the micro dilution method as 153 
described previously (40). Briefly, overnight bacterial cultures were adjusted to an OD600 of 154 
0.8 and diluted 1:100 in TSB to produce a bacterial inoculum for susceptibility testing. 155 
Inocula were incubated with doubling dilutions of the relevant microbicide at 37ºC for 24 h. 156 
The MIC was defined as the lowest concentration for which bacterial growth did not occur. 157 
Growth was defined as turbidity (496nm) in comparison to an uninoculated well (negative 158 
control). Aliquots (10µl) from wells exhibiting no growth were transferred to sterile TSA and 159 
incubated at 37ºC. The MBC was defined as the lowest concentration of microbicide at which 160 
no bacterial growth occurred after 4d of incubation. 161 
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Disc diffusion tests. Antibiotic susceptibilities were determined for ciprofloxacin 162 
(1μg), cephalothin (30μg), ampicillin (10μg), kanamycin (10μg), tetracycline (10μg), 163 
gentamicin (10μg) and Trimethoprim–sulfamethoxazole (25μg). Disc diffusion assays were 164 
performed according to the standardized British Society for Antimicrobial Chemotherapy 165 
(BSAC) disc diffusion method for antimicrobial susceptibility testing (41). Plates were 166 
incubated for 48 h at 37ºC. 167 
Protein extraction and isoelectric focusing. Bacterial cultures were grown in TSB at 168 
37˚C and 100 rpm for 18h, diluted 1:100 and incubated at 37˚C with shaking at 100rpm to 169 
mid-log phase (OD600 of 0.4). Cultures were pelleted at 12,000 x g, washed in PBS (0.01 M 170 
phosphate buffer, 0.0027M potassium chloride and 0.137M sodium chloride, pH 7.4, 3 x 171 
3ml) and resuspended in PBS (1ml). To extract protein, lysostaphin (50μg/ml) was added and 172 
the suspensions were incubated for 15min on ice prior to sonication at an amplitude of 10µ in 173 
6 x 30 second bursts. Protein was precipitated in a 1:1:8 solution of cell lysate with 174 
trichloroacetic acid (6.1 N) and acetone and incubated at -20˚C for 1h. Protein was pelleted 175 
by centrifugation at 16,000 x g, washed three times in acetone (1ml) and dissolved in  176 
rehydration buffer (9M urea, 2% CHAPS, 1% DTT, 2% carrier ampholytes, 0.5% protease 177 
inhibitor, 0.001% bromophenol blue, 2 ml). Soluble protein concentration was quantified 178 
using the Bradford assay (Sigma, Poole, UK). Between 250 μg and 500 μg of protein per 200 179 
μl total volume of buffer was loaded per 11cm ReadyStripTM immobilised protein gradient 180 
(IPG) strip pH 5-8 (Bio-Rad, Hertfordshire, UK). Strips were rehydrated under active 181 
conditions overnight using a PROTEAN IEF cell (Bio-Rad, Hertfordshire, UK). After 182 
rehydration, isoelectric focusing was conducted as follows; 250V for 15 min, linear voltage 183 
to 8000V, 500V until the run was completed.  184 
Two dimensional gel electrophoresis.  IPG strips were equilibrated using  185 
equilibration buffer 1 (6M urea, 2% SDS, 50mM Tris-HCL pH 8.8, 2% glycerol and 1% 186 
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DTT, 5 ml) followed by  equilibration buffer 2 (6M urea, 2% SDS, 50 mM Tris-HCL pH 8.8, 187 
2% glycerol and 2.5% iodoacetamide, 5 ml). Polyacrylamide casting gels (34ml distilled 188 
water, 25ml 1.5 M Tris-HCL pH 8.8, 0.5ml of 20% SDS and 40 ml of 30% bis-acrylamide) 189 
were polymerised by the addition of 10% ammonium persulphate (0.5ml) and  190 
tetramethylethylenediamene (TEMED) (100μl). Stacking gel solution (34 ml distilled water, 191 
6.25ml of 1 M Tris-HCL, 0.25ml of 20% SDS, 8.5ml of 30% bis-acrylamide, 0.25 ml APS 192 
and 50μl TEMED) was poured above the set casting gel and IPG strips were loaded above the 193 
stacking gel. Gels were run at 20V for 1-2h, then at 55V for 15-18h before being fixed for 8h 194 
(500ml ethanol, 400ml water and 100ml acetic acid) at room temperature and stained with a 195 
coomassie blue stain (0.8g coomassie blue R350, 400 ml of 40% methanol and 400 ml 20% 196 
acetic acid) for 18h at room temperature and 20rpm. After destaining, (500ml methanol, 197 
400ml water and 100ml acetic acid) gel spots of interest were excised and proteins were 198 
identified using tandem mass spectrometry, performed at The Biomolecular Analysis Facility 199 
within The University of Manchester.  200 
Transmission electron microscopy.  Cultures (50ml) were grown to an OD600 of 0.3 201 
in TSB and bacterial cells were pelleted via centrifugation at 16,000 x g for 10min. Cells 202 
were resuspended in 0.25% gluteraldehyde (1ml) at 4˚C, further fixed in 2% osmium 203 
tetroxide and passed through an ethanol dehydration series. Cells were sectioned (80nm) and 204 
TEM was conducted using a FEI Polara 300kV FEG transmission electron microscope (FEI, 205 
Oregon, USA) at The University of Manchester imaging suite. 206 
Competitive fitness assay.  Competitive fitness was assessed using methods outlined 207 
previously (42). Overnight cultures of S. aureus P0 or P10 were diluted 1:10 and adjusted to 208 
an OD600 of 1.5. Sterile TSB (250ml) was inoculated in triplicate with P0 or P10, alone or in 209 
combination (final inoculum volume, 500µl). Flasks were incubated at 37˚C with shaking at 210 
100 rpm for 24 h. At 0 h and 24 h, dilutions from each flask (10-2 to 10-6) were plated onto 211 
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TSA and TSA containing 1μg ml-1 triclosan (TSATCS) in triplicate and incubated at 37˚C for 212 
18h. Bacterial viable counts were determined after 18h of incubation, and relative fitness was 213 
assessed for bacteria grown independently and in combination, using the equation; W= ln 214 
(RF/RI)/ ln (SF/SI) where W refers to relative fitness, RI and SI refer to the number of SCV 215 
and susceptible cells at the start point, respectively and RF and SF to the number of SCV and 216 
susceptible cells at endpoint.  217 
 218 
RESULTS 219 
           Altered triclosan and antibiotic susceptibility in triclosan-exposed S. aureus. In 220 
addition to the SCV (R1), previously induced by the exposure of S. aureus ATCC 6538 to 221 
triclosan (6), SCVs were similarly formed by the replicate triclosan-exposure of S. aureus 222 
ATCC 6538 (R2), as well as by strains Newman, ATCC 43300 and NCTC 13277. Colony 223 
morphology in S. aureus strains NCTC 6571 and NCTC 13142 however, remained 224 
unchanged after repeated triclosan exposure.  225 
Triclosan susceptibility (MIC and MBC) significantly decreased in all P10 strains (SCV and 226 
non-SCV) when compared to the respective parent strains (Table 1 P<0.01). After passage in 227 
the absence of triclosan (X10) MICs and MBCs frequently partially reverted but remained 228 
significantly higher than the pre-exposure values for all test strains (P<0.01). When 229 
comparing the susceptibility of the P0 to P10 strains, for SCVs, increases in MIC ranged 230 
from 4 to 31-fold whilst increases in MBC ranged from 3 to 16-fold. In comparison, for non-231 
SCV strains MICs increased from 5 to 11-fold whilst MBCs increased from 4 to 8-fold. 232 
 In terms of antibiotic susceptibility, our previously formed S. aureus ATCC 6538 R1 showed 233 
a significant increase in sensitivity to all test antibiotics with the exception of ampicillin, 234 
when compared to the parent strain (Table 2; P<0.05). Antibiotic susceptibilities partially 235 
reverted to pre-exposure values when the SCV was allowed to recover in the absence of 236 
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triclosan. However, susceptibilities of X10 remained significantly higher than the parent 237 
strain for cephalothin, gentamicin, kanamycin, and thiomethoprim-sulfamethoxazole 238 
(P<0.05). Replicate SCV strain ATCC 6538 R2 also exhibited a significant increase in 239 
susceptibility to cephalothin, gentamicin and tetracycline, which remained elevated in the 240 
absence of triclosan for cephalothin and gentamicin (X10; P<0.05). S. aureus ATCC 43300 241 
(SCV) increased in susceptibility to all test antibiotics with the exception of gentamicin, 242 
kanamycin and ciprofloxacin however, all increases in susceptibility fully or partially 243 
reverted back to pre-exposure levels once the bacteria were passaged without triclosan (X10; 244 
P<0.05). S. aureus NCTC 13277 (SCV) was more susceptible to gentamicin and 245 
trimethoprim-sulfamethoxazole after triclosan exposure, whilst X10 strains showed no 246 
significant difference in susceptibility when compared to the unexposed parent strain (P0). S. 247 
aureus Newman (SCV) exhibited increased susceptibility to ciprofloxacin, cephalothin, 248 
kanamycin, gentamicin and a decrease in trimethoprim-sulfamethoxazole susceptibility; 249 
however X10 strains only showed a significantly different susceptibility than P0 to 250 
trimethoprim-sulfamethoxazole and cephalothin. In non-SCV forming strains, NCTC 6571 251 
exhibited a significant increase in cephalothin susceptibility after repeated triclosan exposure, 252 
whilst NCTC 13142 showed a reduction in trimethoprim-sulfamethoxazole susceptibility, 253 
neither of which fully reverted to pre-exposure levels in the absence of triclosan, (P<0.05). 254 
Two-dimensional (2D) gel electrophoresis of a parent and triclosan-exposed 255 
strain of S. aureus ATCC 6538 revealed differences in protein expression. Proteins of 256 
interest were identified using tandem mass spectrometry (MS-MS) after electrospray 257 
ionisation (Figure 1A-B). Notably, upregulation of triclosan target enzyme FabI was 258 
observed in the SCV strain. There was an evident increase in peptide deformylase (Def) 259 
production after triclosan exposure, which is a participant in protein synthesis in bacteria. A 260 
possible increase in expression of transglycosylase IsaA, an autolysin involved in cell wall  261 
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cleavage during cell replication, was also detected in the SCV strain.  262 
A triclosan-adapted S. aureus ATCC 6538 SCV exhibits abnormal cell 263 
morphology. The internal cellular morphologies of S. aureus parent strain (P0), SCV (P10) 264 
and recovered X10 strain were visualised using TEM (Figure 2). High-resolution 265 
micrographs revealed that the SCV exhibited a higher frequency of irregular-shaped or 266 
abnormally dividing cells due to asymmetrical septum formation. The mean diameter of the 267 
SCV cells were on average 32.8% and 28.3% greater than those of the P0 or X10 strain 268 
respectively (P<0.001). There was no significant difference between the diameters of P0 and 269 
X10.  270 
Altered cationic microbicide susceptibility in a triclosan induced S. aureus 271 
ATCC 6538 SCV. When compared to P0, MICs for polyhexamethylene biguanide (PHMB), 272 
chlorhexidine and benzalkonium chloride significantly decreased in the S. aureus SCV (P10) 273 
from 3.6 µg/ml to 1.8 µg/ml for benzalkonium chloride and chlorhexidine and from 15.6 274 
µg/ml to 3.6 µg/ml for PHMB (P<0.001; Table 3). MBCs of both the biguanides were also 275 
significantly decreased in P10 from 93.8 µg/ml to 31.6 µg/ml for PHMB and from 15.6 276 
µg/ml to 7.8 µg/ml for chlorhexidine. The MBC for Benzalkonium chloride (BAC) did not 277 
change between P0 and P10 (Table 3). After passage in the absence of triclosan (X10), the 278 
MIC of PHMB partially reverted to the pre-exposure level, whereas MICs of chlorhexidine 279 
and BAC did not revert. In terms of bactericidal activity, MBCs of PHMB and chlorhexidine 280 
fully reverted to pre-exposure levels in the absence of any microbicide (X10).  281 
Reduced competitive fitness of a S. aureus ATCC 6538 SCV compared to the 282 
parent strain. The overall productivity (cfu/ml) of P10 after 24 h of growth was significantly 283 
lower than that of P0. This deficit in growth was substantially more pronounced when the 284 
strains were grown in competition (Figure 3). The relative Darwinian fitness (W) of P0 and 285 
P10 was compared when grown separately and when in competition with each other (Figure 286 
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3). By definition a relative fitness of 1 indicates no fitness effect between strains, a value of 287 
below 1 implies impaired fitness and above 1 enhanced fitness (42). The relative fitness (W) 288 
of P10 to P0 during individual growth was 0.97, compared to 0.51 during competition. 289 
Therefore, in a non-competitive environment P10 grew 3% slower than P0, whereas when in 290 
a competitive environment P10 grew 49% slower than P0. 291 
 292 
DISCUSSION 293 
In the current investigation, the repeated exposure of S. aureus to triclosan selected for 294 
substantially reduced triclosan susceptibility in 6/6 test strains whilst only 4/6 formed the 295 
SCV phenotype. In SCVs, antibiotic susceptibility significantly increased in 3/5 strains for 296 
tetracycline, 2/5 for kanamycin, 5/5 for gentamicin, 3/5 for trimethoprim-sulfamethoxazole, 297 
1/5 for ampicillin, 2/5 for ciprofloxacin and 4/5 for cephalothin. The only decrease in 298 
antibiotic susceptibility observed in a SCV was in S. aureus Newman for trimethoprim-299 
sulfamethoxazole, which reverted in the absence of triclosan. In the two non-SCV forming 300 
strains, only NCTC 6571 showed a significant increase in antibiotic susceptibility after 301 
triclosan exposure (to cephalothin), whilst non-SCV forming strain NCTC 13142 showed a 302 
significant decrease in trimethoprim-sulfamethoxazole susceptibility. S. aureus strain ATCC 303 
6538 SCV R1 exhibited the largest increase in both triclosan and antibiotic susceptibility 304 
when compared to the P0 and was therefore further evaluated for alterations in protein 305 
expression, competitive fitness, cationic microbicide susceptibility and cellular morphology. 306 
Proteomic analysis of the S. aureus ATCC 6538 SCV R1 (P10) and parent strain (P0) 307 
revealed changes in protein expression after repeated sub-lethal triclosan exposure, notably 308 
an upregulation of triclosan target enzyme FabI, which may explain previously observed 309 
decreases in triclosan susceptibility (6). An increase in the expression of peptide deformylase, 310 
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Def, a metalloenzyme involved in protein synthesis, may indicate an overall elevation in 311 
protein synthesis in the SCV (43), possibly as part of a generalised stress response. An 312 
increase in IsaA expression was also observed in this SCV strain. A major role of this 313 
enzyme is the hydrolysis of bonds within peptidoglycan thus allowing cell wall expansion 314 
and cell growth (44). TEM analysis of cell morphology revealed a high proportion of SCV 315 
cells with an abnormal shape and impaired septation, resulting in significantly larger cells 316 
than the parent (P0) and the partly recovered (X10) strains. It is therefore possible that the 317 
over-expression of IsaA may occur in response to this morphological defect, in an attempt to 318 
compensate for the lack of cell division observed in this SCV strain. Both thymidine and 319 
haemin auxotrophic SCVs have previously presented as enlarged cocci with multiple cross 320 
walls when viewed using scanning electron microscopy (13), which is consistent with the 321 
impaired cell septation observed in the current SCV. However, previous analysis of this SCV 322 
strain revealed no auxotrophy for thymidine or haemin (6). This defective cell division may 323 
help further account for the reduced growth rate and small colony size of the SCV when 324 
compared to the parent (P0) strain. 325 
The generation of S. aureus SCVs by exposure to various antimicrobials, has been previously 326 
associated with decreased susceptibility to certain antibiotics, cationic microbicides and 327 
recently, to human antimicrobial peptides (8, 45). This reduction in susceptibility is often 328 
attributed to defects in the electron transport chain, as well as reduced growth rates and 329 
hypermutability (11, 16, 19). In contrast, in the present study a triclosan-induced SCV in S. 330 
aureus strain ATCC 6538 (R1) exhibited increased susceptibility to 6/7 test antibiotics and to 331 
the cationic microbicides PHMB, chlorhexidine and BAC. Interestingly, the only antibiotic to 332 
which this SCVs susceptibility did not increase significantly towards was ampicillin, a 333 
transpeptidase inhibitor that interferes with bacterial cell wall formation. TEM revealed 334 
impaired cross-wall formation in the SCV strain and proteomic analysis suggested an 335 
14 
 
increase in expression of IsaA a lytic transglycoylase involved in the hydrolysis of 336 
peptidoglycan and thus cell wall expansion, turnover and cell growth (44). The 337 
overexpression of IsaA may represent an adaptation to this functional deficit. Such 338 
phenotypic compensation may reduce the effectiveness of ampicillin, potentially ameliorating 339 
susceptibility increases in this SCV. Impairments in cell wall synthesis leading to a possible 340 
increase in cell wall permeability may further explain why P10 was more susceptible to the 341 
majority of antibiotics, as well as to the membranotopic cationic microbicides.  342 
When comparing the relative fitness of the parent (P0) and SCV (P10) strains in S. aureus 343 
ATCC 6538 SCV (R1), P10 grew at a 3% lower rate than P0 when grown independently, but 344 
was 49 % slower when grown in competition, highlighting the competitive advantage of the 345 
P0 strain. The impaired ability of this SCV to undergo cell division may in part help account 346 
for this reduced relative fitness. Previous investigations have demonstrated fitness costs 347 
associated with antimicrobial resistance (23, 46, 47). It has been theorised that the fitness of a 348 
bacterium is directly proportional to its rate of transmission and ability to compete with other 349 
strains within the host, and this may be inversely proportional to its rate of clearance from the 350 
host (48). Therefore, fitness however measured, may be an important predictor of the clinical 351 
significance and potential for environmental persistence of a bacterium. For example, a 352 
bacterium acquiring a mutation that results in antimicrobial resistance but also in a fitness 353 
burden, may not establish in its environment due to reduced competitive fitness. 354 
Alternatively, the bacterium could persist at low level for a prolonged period. However, if an 355 
adapted bacterium cannot compete with its congeners or has a markedly reduced specific 356 
growth rate then its pathogenic capability may be reduced (23). When grown in binary 357 
culture with the mother strain, the triclosan-induced SCV in S. aureus ATCC 6538 (R1) in 358 
the current investigation was outcompeted indicating the functional implications of 359 
adaptation.  360 
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CONCLUSION 361 
Repeated exposure to triclosan may select for SCVs in S. aureus exhibiting reduced triclosan 362 
susceptibility but significantly increased susceptibility to certain antibiotics. In an SCV 363 
generated from S. aureus ATCC 6538, reduced triclosan susceptibility may be partly 364 
attributed to the overexpression of target enzyme FabI. This SCV also exhibited impaired 365 
competitive fitness which may be due to defective cell division and an associated reduction in 366 
planktonic growth. Additionally, this SCV strain showed increased susceptibility towards 6/7 367 
test antibiotics and all tested cationic microbicides.  Unlike previous reports, the formation of 368 
the SCV phenotype in triclosan exposed S. aureus ATCC 6538, appears not to be due to 369 
defects in haemin, menadione or thymidine synthesis but possibly due to impairment in cell 370 
wall formation.  371 
 372 
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TABLE 1. Triclosan susceptibility of Staphylococcus aureus before, during and after 536 
repeated triclosan exposure 537 
Test bacterium        MIC    MBC P0 P10 X10   P0 P10 X10 
Staphylococcus aureus  ATCC 6538 R1* 1 31 7  4 63 14 (4) 
Staphylococcus aureus ATCC 6538 R2* 2 (1) 21 (8) 14 (4)  8 (3) 94 (34) 29 (6) 
Staphylococcus aureus NCTC 6571 2 21 (8) 16  17 (6) 63 31 
Staphylococcus aureus Newman* 4 16 16  31 125 63 
Staphylococcus aureus ATCC 43300*  2 16 14 (3)  21 (6) 63 41 (17) 
Staphylococcus aureus NCTC 13277* 4 18 (6) 14 (3)  16 63 57 (13) 
Staphylococcus aureus NCTC 13142 4 18 (6) 16  16 125 47 (17) 
Mean minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) 538 
(µg/ml) of S. aureus before triclosan exposure (P0), after sub-lethal triclosan exposure (P10) and after 539 
recovery in a triclosan-free environment (X10). Data show duplicate experiments with three technical 540 
replicates. When data varied between replicates standard deviations are given in the parenthesis. Bold 541 
text indicates a statistically significant difference (P<0.001) in MIC or MBC compared to that of the 542 
parent strain (P0). *Indicates strains that formed SCV after triclosan exposure. R1 and R2 indicate 543 
replicates 1 and 2 respectively. 544 
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TABLE 2. Antibiotic susceptibility in Staphylococcus aureus before, during and after repeated triclosan exposure 545 
S. aureus   
TET KAN GEN SXT AMP CIP CEF 
P0 P10 X10 P0 P10 X10 P0 P10 X10 P0 P10 X10 P0 P10 X10 P0 P10 X10 P0 P10 X10 
ATCC 6538 R1*  26 (1) 29 (1) 25 (1) 20 (1) 29 (1) 25 (1) 21 (1) 29 (1) 24 (1) 29 (1) 37 (1) 33 (1) 44 (1) 46 (3) 46 (2) 24 (2) 27 (2) 23 (1) 43 (1) 45 (1) 44 (1) 
ATCC 6538 R2* 27 (1) 30 (1) 28 (2) 18 (1) 19 (1) 19 (1) 21 (1) 26 (1) 24 (1) 28 (1) 27 (1) 26 (2) 45 (3) 48 (4) 48 (1) 25 (2) 24 (2) 23 (3) 43 (1) 47 (1) 45  
NCTC 6571  25 (3) 25 (4) 26 18 (2) 17 (2) 17 (1) 22 (3) 22 (1) 21 (1) 28 (3) 26 (2) 27 (1) 44 (4) 42 (2) 43 (1) 28 (3) 28 (2) 27 (1) 37 (1) 43 (1) 41 (1) 
NEWMAN*  28 (2) 29 (1) 26 (1) 14 (3) 20 (1) 16 25 (3) 29 (2) 23 (1) 20 (1) 18 (1) 22 (1) 18 (2) 19 (1) 18 (1) 26 (2) 30 (1) 23 (2) 33 (1) 37 (1) 35 (1) 
ATCC 43300*  25 (1) 32 (1) 30 (1) 0 0 0 9 (1) 32 (1) 28 (1) 26 (3) 30 26 (1) 15 (2) 22 (1) 18 (1) 22 (1) 21 (1) 22 (1) 27 (1) 48 (1) 46 (1) 
NCTC 13277*  31 (4) 30 (1) 28 (1) 0 0 0 22 (4) 29 (1) 23 (2) 27 (4) 29 (1) 25 (1) 11 11 (1) 10 (1) 0 0 0 0 0 0 
NCTC 13142  27 (3) 28 (1) 28 (1) 15 (4) 15 (2) 16 (1) 23 (1) 22 (2) 23 (2) 29 (2) 25 (2) 25 (1) 12 (2) 13 (1) 13 20 (4) 23 (1) 23 (2) 28 (1) 28 (1) 28 (1) 
Antibiotic disc diffusion zones of inhibition (mm) of S. aureus before triclosan exposure (P0), after sub-lethal triclosan exposure (P10) and after recovery in a triclosan-free environment (X). 546 
TET, tetracycline; KAN, kanamycin; GEN, gentamicin; SXT, trimethoprim-sulfamethoxazole; AMP, ampicillin; CIP, ciprofloxacin; CEF, cephalothin Data show duplicate experiments each 547 
with three technical replicates. When data varied between replicates standard deviations are given in the parenthesis. Bold text indicates a statistical difference (P<0.05) in inhibition zone size 548 
when compared to that of the parent strain (P0). *Indicates strains that formed SCV after triclosan exposure (P10). 549 
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TABLE 3. The susceptibility of Staphylococcus aureus ATCC 6538 to cationic microbicides 550 
before, during and after repeated triclosan exposure 551 
Microbicide MIC  MBC  
 P0 P10 X10 
 
P0 P10 X10 
Benzalkonium chloride 3.6 1.8 1.8 15.6 15.6 15.6 
Chlorhexidine 3.6 1.8 1.8 15.6 7.8 15.6 
Polyhexamethylene biguanide 15.6 3.6 7.8 93.8 (34) 31.2 93.8 (34) 
Mean minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) 552 
(µg/ml) of S. aureus ATCC 6538 before triclosan exposure (P0), after sub-lethal triclosan exposure 553 
(P10; SCV) and after recovery in a triclosan-free environment (X10). Data show duplicate 554 
experiments with three technical replicates. When data varied between replicates standard deviations 555 
are given in the parenthesis. Bold text indicates a statistically significant difference (P<0.001) in MIC 556 
or MBC compared to that of the parent strain (P0). 557 
558 
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FIG. 1 559 
 560 
561 
Spot Identity Function Accession no. 
1 FabI 
                                                                            
Enoyl-[acyl-carrier-protein] reductase 
involved in fatty acid synthesis 
 
FABI_STAAR 
2 IsaA 
                                                                            
Transglycolsylase involved in the cleavage of 
peptidoglycan. 
 
ISAA_STAA1 
3 Def Peptide deformylase involved in protein translation. DEF_STAAC 
P10 
FIG. 1. A) 2D gels showing protein expression profiles in P0 and P10 strains of S. 
aureus ATCC 6538. Proteins of interest were excised and identified using esi MS-
MS. Indicated proteins were identified as FabI (1) IsaA (2) and Def (3). B) Identities 
and functions of proteins selected from 2D gels of S. aureus ATCC 6538 that were 
upregulated in triclosan induced SCVs. 
1 
2 
3 
B 
A 
P0 
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 562 
 563 FIG. 2. A) Cellular morphology of S. aureus ATCC 6538 parent strain P0, P10 and X10 564 
strains visualised by TEM. B) Mean cell diameter P0 (black), P10 (white) and X10 (grey).  565 
The asterisk indicates the significant difference in cell diameter of P10 when compared to P0 566 
or X10 (P <0.001). 567 
FIG. 2 
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 568 
FIG 3. Competitive fitness of P0 vs P10 (SCV) in S. aureus ATCC 6538. Black and grey 569 
bars show cfu/ml of P0 and P10, respectively after 24h of growth, axenically or in binary 570 
culture. White bars indicate relative fitness (W) under axenic and binary growth. Data are 571 
means and standard deviations from four separate experiments with three technical replicates. 572 
Error bars show standard deviation. Asterisks indicate statistically significant differences 573 
(P<0.001) compared to the parent strain (P0).  574 
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